Showing results (91-100 of 137) with videos related to
Sort By:
Pageof 14
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.British Journal of Haematology|January 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.Nature Communications|June 8, 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hubRocco Piazza, Vera Magistroni, Sara Redaelli, et al.British Journal of Haematology|January 6, 2021
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemiaSimona Soverini, Margherita Martelli, Luana Bavaro, et al.Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.American Journal of Hematology|July 17, 2015
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV studySilvia Mori, Elisabetta Vagge, Philipp le Coutre, et al.Pageof 14